PCM
ACAD icon

Portolan Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Portolan Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-44,850
Closed -$1.48M – 124
2015
Q3 		$1.48M Sell
44,850
-60,163
-57% -$2.5M 0.2% 104
2015
Q2 		$4.4M Sell
105,013
-3,066
-3% -$119K 0.62% 59
2015
Q1 		$3.52M Sell
108,079
-42,214
-28% -$1.45M 0.65% 60
2014
Q4 		$4.77M Buy
150,293
+91,643
+156% +$2.6M 0.96% 43
2014
Q3 		$1.45M Buy
+58,650
New +$1.37M 0.33% 88

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Portolan Capital Management's ACAD Position: Q4 2015 in Review

Portolan Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2015, closing a stake of 44,850 shares — an estimated $1.48M sold.

Portolan Capital Management first reported a position in ACAD in Q3 2014 and held it in 5 quarters. The position peaked at $4.77M in Q4 2014. 215 funds tracked by Wall St. Rank hold ACAD as of Q4 2015.

  • Portolan Capital Management reported no remaining Acadia Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Portolan Capital Management sold 44,850 Acadia Pharmaceuticals shares in Q4 2015, an estimated $1.48M.
  • Portolan Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2014 and held it in 5 quarters.
  • Portolan Capital Management's Acadia Pharmaceuticals position peaked at $4.77M in Q4 2014.
  • 215 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2015.

Based on Portolan Capital Management's 13F filing for Q4 2015, filed 12 Feb 2016.